Clinical Trials Browser

Phase 1/2 × OTHER × AFM13 × Clear all

NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Phase 1/2 Completed

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT03192202 2023-07-20

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Phase 1/2 Completed

18 enrolled 9 charts

DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous